Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors
July 16, 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, July 16, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 29, 2018 16:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, June 29, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics to Present at UBS Global Healthcare Conference
May 15, 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, May 15, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results
May 08, 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, May 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics Prices Public Offering of Common Stock
April 18, 2018 22:50 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 18, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
April 17, 2018 16:01 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics Meeting
April 12, 2018 07:00 ET
|
Aeglea BioTherapeutics, Inc.
Clinical Outcome Assessment Tools Detected and Quantified Baseline Abnormalities Clinically Relevant Improvement Seen in Multiple Neuromotor Tests Company to Host Clinical Update Conference Call...
Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting
April 05, 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 05, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting
April 03, 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 03, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials
April 02, 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 02, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...